Show simple item record

dc.contributor.authorRoblin, P M
dc.contributor.authorHammerschlag, M R
dc.date.accessioned2023-06-30T16:37:51Z
dc.date.available2023-06-30T16:37:51Z
dc.date.issued1998-01
dc.identifier.citationRoblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother. 1998 Jan;42(1):194-6. doi: 10.1128/AAC.42.1.194. PMID: 9449287; PMCID: PMC105482.en_US
dc.identifier.issn0066-4804
dc.identifier.pmid9449287
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10344
dc.description.abstractChlamydia pneumoniae was eradicated from the nasopharynges of 26 of 33 (78.8%) evaluable children and adults with community-acquired pneumonia who were treated with azithromycin. We tested 55 isolates of C. pneumoniae obtained from 46 of these patients against azithromycin. The MIC at which 90% of the isolates were inhibited and the minimal chlamydiacidal concentration at which 90% of strains tested were killed of azithromycin for these isolates were both 0.5 microg/ml. Seven patients remained culture positive after treatment. The MICs of azithromycin for isolates from two patients increased fourfold after therapy. However, all the patients with persistent infection improved clinically. Further studies of treatment of C. pneumoniae infection, utilizing culture, are needed both to assess efficacy and to monitor for the possible development of antibiotic resistance.
dc.language.isoenen_US
dc.relation.urlhttps://journals.asm.org/doi/epub/10.1128/aac.42.1.194en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleMicrobiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAntimicrobial agents and chemotherapyen_US
dc.source.volume42
dc.source.issue1
dc.source.beginpage194
dc.source.endpage6
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-06-30T16:37:51Z
html.description.abstractChlamydia pneumoniae was eradicated from the nasopharynges of 26 of 33 (78.8%) evaluable children and adults with community-acquired pneumonia who were treated with azithromycin. We tested 55 isolates of C. pneumoniae obtained from 46 of these patients against azithromycin. The MIC at which 90% of the isolates were inhibited and the minimal chlamydiacidal concentration at which 90% of strains tested were killed of azithromycin for these isolates were both 0.5 microg/ml. Seven patients remained culture positive after treatment. The MICs of azithromycin for isolates from two patients increased fourfold after therapy. However, all the patients with persistent infection improved clinically. Further studies of treatment of C. pneumoniae infection, utilizing culture, are needed both to assess efficacy and to monitor for the possible development of antibiotic resistance.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAntimicrobial agents and chemotherapy
dc.identifier.issue1en_US


Files in this item

Thumbnail
Name:
aac.42.1.194.pdf
Size:
109.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International